Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

NEXT STORY
ABM Establishes Expert Advisory Council to Support COVID-19 Response and EnhancedClean™ Program
PREV STORY
Harpoon Therapeutics Announces Changes to Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medtronic Initiates PRODIGY – a Global Study to Identify Those at High Risk for Opioid Induced Respiratory Depression, a Preventable Form of Respiratory Compromise

DUBLIN - May 31, 2017 - Medtronic plc (NYSE: MDT) recently launched PRODIGY, a ...

author_avatar
NASDAQ Market News

7 Hills Pharma Appoints Lionel D. Lewis as Chief Medical Officer

HOUSTON, July 24, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company ...

author_avatar
NASDAQ Market News

Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017

Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017 ...

author_avatar
NASDAQ Market News